| Document |
Document Title |
|
WO/2017/021922A1 |
The present invention relates to compounds of novel substituted amides of triteripene derivatives of formula (I); or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, tautomers...
|
|
WO/2017/017609A1 |
The present invention relates to compounds characterized by having a structure according to the following Formula I, or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or preven...
|
|
WO/2017/017607A1 |
The present invention relates to compounds characterized by having a structure according to the following Formula (I), or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prev...
|
|
WO/2017/017630A1 |
The present invention relates to novel betulinic substituted amide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y, Z1, Z2, Z3 and are Formula (II) as defined herein. ...
|
|
WO/2016/193309A1 |
The present invention relates to synthetic bis esters of hederagenin, and their use in ruminants to improve ruminant growth performance, reduce rumen methane emission, reduce urine ammonia excretion, and/or to reduce rumen acetate to pro...
|
|
WO/2016/184400A1 |
The present invention relates to a novel 18α-glycyrrhetinic acid derivative and pharmaceutical use thereof. The compound has a weak inhibitory activity on 11β-hydroxyl steroid dehydrogenase, thus effectively alleviating an adrenocortic...
|
|
WO/2016/135553A1 |
The present invention relates to a protoescigenin derivative of formula (I) having pharmacological properties, process of its preparation, use of such compound as medicament especially for treating vascular disorders, as well as to a pha...
|
|
WO/2016/086453A1 |
Disclosed are a use of a pentacyclic triterpenoid compound in preparing a cholesterol ester transfer protein (CETP) inhibitor, and a pharmaceutical composition thereof.
|
|
WO/2016/086496A1 |
The present invention relates to the technical field of biopharmaceutical. Provided is a pentacyclic triterpenoid compound and use thereof as human carboxylesterase inhibitor. The pentacyclic triterpenoid compound has a 11-deoxygenate-gl...
|
|
WO/2016/077561A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhib...
|
|
WO/2016/077569A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhib...
|
|
WO/2016/077572A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhib...
|
|
WO/2016/039359A1 |
The present invention relates to: a terpenoid derivative which is capable of activating a Keap1/Nrf2/ARE signaling pathway and has an excellent anti-inflammatory activity and an excellent cell-protecting activity; and a sustained-release...
|
|
WO/2016/029888A1 |
The present invention provides amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use as medicaments for treating neuropsychiatric disorders associated with an ...
|
|
WO/2016/001820A1 |
The present invention relates to novel betulinic proline imidazole derivatives and related compounds, compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.
|
|
WO/2015/195776A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivaties that possess unique antiviral activity are provided as HIV maturation inhibi...
|
|
WO/2015/166462A1 |
The invention relates to a method for isolating and purifying 3-O-acetyl-11-keto-β- boswellic acid (AKBA) from an extract containing a mixture of boswellic acids obtained from the gum resin ofBoswelliaspecies. The method comprises the s...
|
|
WO/2015/157483A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as rep...
|
|
WO/2015/135449A1 |
The present invention relates to a pentacyclic triterpenoid compound represented by general formula (I) and preparation method thereof, pharmaceutical composition comprising the compound, uses of the compound in preparation of drugs for ...
|
|
WO/2015/135474A1 |
Disclosed are a pentacyclic triterpene compound represented by general formula (I) and pharmaceutical compositions containing the compound. Also disclosed is use of the compound in preparation of a PS1/BACE1 interaction inhibitor, and us...
|
|
WO/2015/081778A1 |
The present invention belongs to the field of organic synthesis, relates to a method for synthesizing a saponin, and in particular, to a method for constructing a glycosidic bond in a saponin, and comprises the following steps: directly ...
|
|
WO/2015/078321A1 |
The present invention relates to a pentacyclic triterpenoid compound with a modified structure and a preparation method and use thereof. The compound of the present invention can treat psoriasis effectively. Moreover, the compound of the...
|
|
WO/2015/076325A1 |
[Problem] To provide a novel glycyrrhetinic acid derivative. [Solution] A glycyrrhetinic acid derivative represented by formula (1). (1)
|
|
WO/2015/057862A1 |
The disclosure relates to compositions, methods, and kits comprising gap junction blockers for selectively eradicating leukemic cells in a population or subject, and related methods of treating acute myeloid leukemia, and promoting survi...
|
|
WO/2014/176415A1 |
The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,1
2a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,
12a,14,1 4a,14b-octadecahydropicen-4a-yl)-2,2-difluoroprop...
|
|
WO/2014/154131A1 |
Provided are a caffeoyl substituted pentacyclic triterpene derivative as represented by formula (I) and pharmaceutical composition containing the same. Also provided are uses of the derivative in the preparation of drugs or health-care p...
|
|
WO/2014/148455A1 |
Provided is a novel terpenoid derivative which exhibits anti-inflammatory action and cytoprotective action by activating Keap1/Nrf2/ARE signal transduction pathways. Terpenoid derivative A is represented by formula (1).
|
|
WO/2014/134413A2 |
The present invention is directed to cyrrhetinic alkyl ester compounds, a method of making the compounds, cosmetic compositions containing the compound(s) and methods of using the same for the treatment of inflammation in human skin. The...
|
|
WO/2014/130810A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, alkyl and alkenyl C-3 modified betulinic acid derivatives that possess unique antiviral activity are p...
|
|
WO/2014/123889A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-19 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhi...
|
|
WO/2014/124198A1 |
Naturally-derived compounds having various structures elicit the perception of salty taste, enhance the perception of salty taste of a salt, or act at one or more sodium channels. Food products may include such naturally-derived compound...
|
|
WO/2014/105926A1 |
The invention relates to novel betulinic acid derivatives and related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases. These compounds are esterifie...
|
|
WO/2014/104905A1 |
Process for preparation of 3,24;16,22-di-O,O-isopropylideneprotoescigenin comprises acetonidation of protoescigenin monohydrate in the mixture consisting of 0 - 100% vol. of acetone and 100 - 0% vol. of 2,2-dimethoxypropane, in presence ...
|
|
WO/2014/093941A1 |
The present Invention relates to long acting pharmaceutical compositions of betulin defivatives or pharmaceutically acceptabnle salts thereof, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
|
|
WO/2014/063441A1 |
The present invention relates to a use of a triterpene derivative of formula (I) for producing drugs which can be used for the prevention or treatment of influenza diseases, wherein the substituents are as defined in the specification. T...
|
|
WO/2014/048033A1 |
The present invention relates to polymorphic forms of the compound of Formula (I) (i.e., ethyl 2-cyano-3,12-dioxoIeana-1,9(1l)-dien-28-oate (CDDO ethyl ester)) and methods of using them for treating a variety of disease states such as ca...
|
|
WO/2014/040060A1 |
Disclosed herein are novel C17-alkanediyi and aikenediyl derivatives of oleanolic acid, including those of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of man...
|
|
WO/2014/040073A1 |
Disclosed herein are novel C13-hydroxy derivatives of oleanolic acid, including those of the formula (I): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprisin...
|
|
WO/2014/040056A1 |
Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula (I): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture compri...
|
|
WO/2013/188818A1 |
Disclosed herein are novel A-ring epoxidized triterpenoid compounds and derivatives thereof, including those of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits, and articles ...
|
|
WO/2013/174245A1 |
Disclosed in the present invention are a hederagenin derivative and the preparation method and uses thereof, and the general formula of the derivative is (I). The preparation method is as follows: the derivative can be obtained via acyla...
|
|
WO/2013/169578A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that possess unique antiviral activity are provided as HIV matur...
|
|
WO/2013/163344A1 |
The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-1 1-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a
,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b- octadecahydropicen-4a-yl)-2,2-difluoroprop...
|
|
WO/2013/155865A1 |
Disclosed is a liquid fermentation method for increasing the yield of total triterpene compounds in Phellinus igniarius. In the method, an expansin is used in the liquid fermentation of total triterpene compounds in Phellinus igniarius, ...
|
|
WO/2013/123019A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-3 cycloalkenyl triterpenoids that possess unique antiviral activity are provided as HIV maturation i...
|
|
WO/2013/117137A1 |
Disclosed are lupane triterpenoid derivatives and pharmaceutical use thereof, specifically lupane triterpenoid derivatives of formulae (I)~(III), a pharmaceutical composition and a combination preparation comprising said lupane triterpen...
|
|
WO/2013/091144A1 |
The present invention relates to a compound characterized by the following Formula I or a pharmaceutically acceptable salt thereof, wherein X, Y, and Z are as described herein. Compounds of the present invention are useful for the treatm...
|
|
WO/2013/079018A1 |
The present invention relates to the fields of natural medicaments and pharmaceutical chemistry, and relates specifically to, as represented by formula (I), a novel 2-substituted oleanolic acid derivative or a pharmaceutically acceptable...
|
|
WO/2013/079024A1 |
The present invention belongs to the fields of natural medicine and medicinal chemistry, and relates particularly to new oleanolic acid amidate derivatives of general formula I or pharmaceutically acceptable salts thereof, preparation me...
|
|
WO/2013/071722A1 |
A method for producing 30-halogenated betulinic acid. Betulin is used as a raw material, and is selectively oxidized and halogenated to generate 30-betulinic acid, and the selected oxidation and halogenation agent has high selectivity an...
|
